Introduction
Patients with cancer are at increased risk to develop venous thromboembolism (VTE), an association that is commonly known as Trousseau's syndrome. 1, 2 The clinical manifestations of cancer-associated VTE include deep vein thrombosis and pulmonary embolism, as well as visceral or splanchnic vein thrombosis. 3 Indeed, cancer is one of the best-established risk factors for VTE. 4, 5 It has been estimated that $20%
of all first VTE events are associated with cancer. 5 According to a recent U.K. cohort study that included 6,592 cancerassociated VTEs, the incidence rate of first VTE in patients with active cancer was 5.8 (95 % confidence interval [CI], 5.7-6.0) per 100 person-years and the overall incidence rate for recurrence was 9.6 (95 % CI, 8.8-10.4) per 100 personyears. 6 Finally, cancer-associated thrombosis is linked with a worse prognosis, and thromboembolism is the second leading cause of death in cancer.
immobility, tumour histology and stage, the presence of indwelling central venous catheters and chemotherapy and/or some molecular targeted therapies. 6 These risk factors, which may be classified as patient-, tumour-or treatment-related, may additively exceed the threshold for clinically overt thrombosis (►Fig. 1).
Tissue factor (TF) is the physiologic activator of coagulation in vivo. We and others have reported elevated levels of TF in the circulation of animal models and in patients with cancer. 7, 8 However, although circulating levels of TF correlate with mortality, it does not always correlate with markers of systemic hypercoagulability, or the occurrence of thrombosis. [9] [10] [11] This suggests that other pathways modulate thrombogenesis in cancer. This review will focus on the hypercoagulable state in cancer with particular reference to recent findings concerning the potential contribution of the contact system (CS) of coagulation.
The Contact System
FXII-Dependent Contact Activation
The CS refers to a proteolytic pathway consisting of the zymogens factor XII (FXII) and prekallikrein (PK), and the non-enzymatic cofactor, high molecular weight kininogen (HK). Some definitions also include zymogen FXI. All component proteins are synthesized and secreted by the liver. 12, 13 Contact of plasma with negatively charged surfaces induces a conformational change in zymogen FXII resulting in a small amount of auto-activated FXII (FXIIa;α-FXIIa), which, in turn, cleaves PK to generate kallikrein (KAL). The conformational change in FXII, together with reciprocal activation of FXII by formed KAL and HK, leads to further formation of FXIIa. [12] [13] [14] [15] The activation of FXII and PK generates a potent activation feedback loop that overcomes inactivation of these enzymes by the principal CS inhibitor, the serpin C1 esterase inhibitor (C1INH). 16 The end result of FXIIa generation may be activated FXI (FXIa) and/or vasoactive and pro-inflammatory kinins, such as bradykinin (BK). FXIa initiates a series of Ca 2þ -dependent proteolytic events that lead to thrombin generation, and production of a fibrin clot. Following the initial generation of thrombin (by whatever mechanism), a powerful amplification mechanism accelerates thrombin formation in a FXI-dependent manner. 16 Additionally, α-FXIIa can be further cleaved by KAL to generate β-FXIIa, which retains the ability to activate PK, but not FXI or FXII, and is able to dissociate from the surface (contact phase). 15, 17, 18 C1INH targets both FXIIa and KAL, accounting for $93% of plasma FXIIa or β-FXIIa inhibition. Furthermore, antithrombin, α 2 -macroglobulin and α 2 -antiplasmin also inhibit FXIIa to a lesser extent (►Fig. 2).
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Apart from glass surfaces, many other negatively charged surfaces or polyanionic molecules, including silica, kaolin, ellagic acid and sulphated polysaccharides, can accelerate contact activation. Certain glycosaminoglycans (GAGs), such as dermatan sulphate, chondroitin sulphate-E and heparin can also initiate contact activation in vitro 18 or in vivo.
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However, over the past decade, intensive research efforts have focused on endogenous 'natural activators' of the CS. Several damage-associated molecular entities have been suggested to directly drive CS activation during vascular injury and infection including extracellular nucleic acids, misfolded aggregated proteins, mast cell heparin and pathogen-related molecules, such as endotoxin. Additionally, inorganic polyphosphate (polyP), a linear polymer of orthophosphates that is present in many infectious microorganisms and is also secreted by mast cells and platelets, has received the most attention. PolyP accelerates blood clotting and slows fibrinolysis, in a manner that is highly dependent on polymer length. Very long-chain polyP (found in many bacteria) is an especially potent trigger of the contact pathway, [26] [27] [28] [29] but aggregated shorter chain polyP in the form of Ca 2þ -dependent nanoparticles may also activate FXII.
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Recently, it was demonstrated that membrane-associated platelet polyphosphate condensed into insoluble spherical nanoparticles on the surface of activated platelets potently activates factor XII. 31 Finally, extravascular matrix proteins such as laminin and collagen are capable of assembling and activating the CS to drive coagulation under flow conditions.
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The FXII-Independent Activation Pathway
An alternate activation mechanism of the CS, independent of FXII, but involving Zn 2þ -and HK-dependent PK activation on endothelial cells, has been described. It has been observed that Fig. 1 Longitudinal risk of thrombosis in a patient with cancer. Normal individuals maintain a haemostatic equilibrium whereas cancer patients are typically in a pre-thrombotic state, and at risk of developing overt thrombosis. The coloured line represents the level of thrombotic risk in a cancer patient following diagnosis as (s)he progresses through various therapeutic interventions that may increase or decrease the basal thrombotic risk induced by the cancer. Thus, the patient may initially receive short-term thromboprophylaxis, which temporally lowers the risk of thrombosis. (S)he may then begin neoadjuvant radiation and/or chemotherapy, leading to an increased risk of thrombosis. When (s)he then undergoes surgery and is immobilized for several days, (s)he crosses the thrombotic threshold and develops a clinically overt thrombotic event. The risk of thrombotic recurrence remains high despite anticoagulation therapy.
KAL activity is generated in FXII-deficient, but not in PK-deficient plasma when HK-PK complexes assemble on the surface of endothelial cells, and HK serves as both the binding site and cofactor for PK activation. 33 In this model, a limited amount of KAL is generated in a FXII-independent manner and is subsequently amplified in a FXII-dependent manner. Moreover, KAL generated on the cell surface then cleaves HK, liberating itself from the complex with HK (its captor and native substrate) and thereby generating BK. Distinct from the FXII-dependent pathway, the alternative pathway is believed to occur constitutively in vivo and is responsible for basal BK formation. 13, 18, 32, 33 Two proteins were proposed to provide the enzymatic impulse for PK activation: both heat shock protein 90 (Hsp90) and the serine enzyme prolylcarboxypeptidase (PRCP) on the surface of endothelial cells have been identified as physiological activators of the KAL/kinin system. 18, 34, 35 Hsp90 and PRCP can activate the PK-HK complex in the absence of FXII but in the presence of Zn 2þ . Notably, HSP90 is very abundant in almost all cell types (2-3% of total cellular proteins) and can be even more abundantly expressed by tumour cells (up to 7% of total protein). 32, 36 Moreover, it has been reported that PK can be auto-catalytically cleaved by KAL, in the presence of certain negatively charged surfaces. 37 As for membrane-mediated activation, apart from endothelial cells, the surfaces of some exogenous microorganisms can also assemble and activate the KAL/kinin system (e.g. the surface of Gram-negative bacteria).
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Measuring Activation of the Contact System in Plasma
Investigation of CS activity can be broadly defined as methods that address the potential for exogenous activation, and those that focus on analysis of in vivo activation. Tools such as clotting assays or substrate cleavage can be used to assess a patient's capacity for CS activation using known initiators, as well as discovery of novel putative physiological activators. Evidence for in vivo activation is predominantly assayed via enzyme-linked immunosorbent assay (ELISA), though Western blot and mass spectrometry have seen specialized use. The most common criticisms applied to these assays are the short half-life of the complexes and the potential for ex vivo activation during collection. Minimization of pre-analytical activation through use of benzamidines or specific CS inhibitors with blood collection 39 is critical and should be considered in study design, since FXII may be rapidly activated ex vivo by contact with blood drawing equipment.
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To our knowledge, there are currently no clinically standardized assays to quantify in vivo activation of the CS, presenting an unmet need in cancer-associated thrombosis research.
Clotting Assays
The activated partial thromboplastin time assay (aPTT) uses an anionic surface to activate FXII following the addition of phospholipid and calcium. Shortened aPTT times (probably driven primarily by elevated FVIII levels) have been linked to an elevated risk of thrombosis, although not specifically in cohorts with cancer. 42 One-stage clotting assays based on aPTT using deficient plasma may be used to detect FXI and XII activity. A reduction in plasma FXII activity has been regarded as a marker of consumption and, thus, indirect evidence of activation of the CS. 43 However, given the global nature of the aPTT-based tests, more specific assays are required to probe the role of the contact pathway in disease states, including cancer-associated thrombosis.
Substrate Cleavage/Chromogenic Assays
Factors XIIa, XIa and KAL are serine proteases and their enzymatic function can be assessed by cleavage of synthetic peptides to generate a chromogenic or fluorogenic signal.
The most commonly used substrate is S-2302 (H-D-Pro-PheArg-pNA), which is sensitive to cleavage by FXIIa and KAL (with a nearly identical Km and Kcat), and to a much lesser extent, FXIa. This substrate mimics the last three amino acids in the BK sequence of kininogen, and may therefore be used to address the role of FXIIa and KAL in liberation of BK from HK. These substrates may be used to assay the activation of potential initiators of the CS in plasma, as demonstrated in a recent report describing prostatic tumour cell-derived exosomes (prostasomes). 44 However, detection of in vivo active enzymes using substrates is not practical nor quantifiable. Furthermore, the cross-reactivity of currently available substrates is problematic; although several more specific substrates for CS enzymes have been developed, the use of specific enzyme inhibitors to minimize the possibility of cross-reactivity should be considered. For example, corn FXIIa is predominantly complexed with C1 inhibitor, which typically accounts for > 90% of inhibition. 20 FXIa is inhibited by α1-antitrypsin ($39%), C1 inhibitor (28%), α2-antiplasmin (28%) and anti-thrombin (5%). However, the addition of heparin greatly increases the contribution of antithrombin in FXIa inactivation ($35% of complexes). 21 C1
inhibitor (55%) and α2-macroglobulin (37%) are the primary inhibitors of KAL, though they have been demonstrated to have different inhibitory rates as well as different clearance rates.
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Thrombosis More recently, heavy chain-only nanobodies specific for FXIIa have been used to distinguish not only between the activation states of FXII, but also between the α and β isoforms. 57 Finally, HK can be cleaved by either FXIIa or KAL to release HK fragments. An ELISA has been developed to detect cleaved HK in plasma as a marker of CS activation (via KAL) due to its longer half-life ($9 hours), 58 but has yet to be applied to cancer-associated thrombosis research.
Western Blot
An alternative approach for detecting activation of the CS activation in plasma is Western blotting. Here, detection of enzyme-inhibitor complexes or cleavage of HK (an indirect measurement of BK release) provide a semi-quantitative measurement of CS activation. 59 Western blotting can offer advantages such as the speciation of FXIIa (α or β) when analysed under reducing conditions, or complexes with inhibitors under non-reducing conditions, without using specific monoclonal antibodies or the aforementioned nanobodies. 60 Detection of heavy chain-only HK by Western blotting has shown sensitivity to concentrations as low as 5 ng/mL, 61 with discernible differences in the plasma of rodent models of BK-mediated diseases. 62 However, due to the low throughput of Western blotting, clinical samples are not typically analysed using this approach.
Mass Spectrometry
The major inflammatory effector of the CS is BK, a 9 amino acid peptide generated from the cleavage of HK by KAL. 67 measured CS activation in 10 lung cancer patient plasmas compared with normal pooled plasma. PK, HK and C1INH were quantified by Western blot. The authors concluded that CS activation was present, as evidenced by cleaved C1INH and C1INH/protease complex in all 10 patients, with absent HK in 9 patients, decreased amounts of PK in 6 and KAL/protease complex in 5. Moreover, the authors confirmed the same CS activation pattern in 11 colon, 9 breast, 3 pancreatic and 1 renal cancer patients. In particular, all of the pancreatic cancer patient samples showed an absence of detectable HK, whereas only one of the colon cancer plasmas had undetectable HK, and this occurred in a patient with stage IV disease (►Table 1).
Mechanisms of Contact System Activation in Cancer
Although several observations documenting activation of the CS in different cancers have been published, the responsible mechanism(s) is poorly understood. As previously mentioned, the variety of assays that have been used makes it difficult to compare results. ►Table 2 summarizes the reported mechanisms of CS activation in cancer.
Microvesicles
Microvesicles (MVs) are submicron, lipid bilayer membrane particles, shed by various cells upon activation or apoptosis. Our group and others have described elevated levels of circulating MVs, including exosomes (MVs of 50-100 nm in diameter) derived from tumour and host blood cells types in cancer patients. [68] [69] [70] [71] Cancer chemotherapy can potentially induce MV release from tumour, blood or endothelial cells.
72
Red cell and platelet transfusions administered to cancer patients are additional sources of MVs. MVs and exosomes may play a major role in tumourigenesis, tumour progression, metastasis and cancer-associated thrombosis.
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As already mentioned, the prothrombotic role of MVs has been mainly ascribed to TF-bearing MVs. 69, 70, 75, 76 However, in a cohort of women with breast cancer, circulating annexin-V positive MVs were elevated and correlated with the stage of the tumour. When analysed according to cellular origin, platelet-derived MVs represented the vast majority (> 80%); their level correlated with plasma levels of prothrombin fragment 1.2, suggesting a role in systemic hypercoagulability. 9 In this study, TF-MV levels were very low and not different from that of women with benign breast Contact System Activation and Cancer Campello et al. 255
tumours, although the correlation with prothrombin fragment was seen only in patients with metastatic cancer. 9 Red blood cell and platelet-derived MVs have previously been shown to activate coagulation through the contact pathway in the context of blood product storage and human endotoxaemia, although here again, the precise molecular trigger for this event remains to be determined. [77] [78] [79] In addition to blood cell-derived MVs, certain tumour-derived exosomes have also been shown to interact with the CS. Exosomes spontaneously released or induced by treatment of the B16 melanoma cell line with doxorubicin in vitro, triggered thrombin and fibrin generation in plasma in the presence of inhibitory TF antibodies. 80 In a mouse model of breast cancer, tumour-derived exosomes cooperated with neutrophils primed by tumour-derived G-CSF to generate NETs and enhance thrombosis (further discussed below). 81 Additionally, exosomes secreted by prostate cancer cells (prostasomes) trigger thrombin generation in vitro in a dosedependent manner, and induce lethal pulmonary embolism in mice. 44 Moreover, the addition of a recombinant FXIIa inhibitor significantly reduced peak and total thrombin generated by prostasomes, and the combined application of FXIIa and TF inhibitors completely blunted thrombin generation. Polyphosphates were found on the surface of prostasomes. Treatment of prostasomes with specific inhibitors of polyphosphates or with polyphosphate degrading enzymes abrogated prostasome-induced FXIIa generation in vitro and protected mice from prostasome-induced lethal pulmonary embolism. However, since similar effects were also observed following inhibition of TF, both the intrinsic and extrinsic pathways seemed to contribute to thrombosis in this model. Further data are required in a diverse range of cancers to understand the role that circulating exosomes/ MVs may play in CS activation.
Cell-Free DNA, Histones and Neutrophil Extracellular Traps
Elevated circulating levels of cell-free DNA (cfDNA) and histones, the major molecular components in nucleosomes/chromatin, are found in cancer patients. They are associated with adverse outcomes and are positively correlated with markers of in vivo coagulation activation such as plasma TAT and D-dimer levels. [82] [83] [84] [85] The mechanisms of extracellular release and the cellular origin of cfDNA and Abbreviations: CS, contact system; F, factor; GAGs, glycosaminoglycans; H3Cit, citrullinated histone H3; MVs, microvesicles; PolyP, polyphosphate; TAT, thrombin-antithrombin complexes; TF, tissue factor; VTE, venous thromboembolism.
histones are unclear, and probably vary according to tumour type, patient co-morbidities and chemotherapy. In cancer patients, cfDNA may be either tumour-derived or released from apoptotic or necrotic non-tumoural tissues, such as neutrophils. 86 Cancer chemotherapy is associated with increased plasma levels of cfDNA. 81,100,101 Animal models have suggested that NETosis plays a major role in cancerassociated thrombosis. In a mouse model of mammary carcinoma, tumour-bearing mice developed a leukaemoid reaction and spontaneous delayed onset thrombosis within the lungs. Interestingly, the percentage of circulating hypercitrullinated neutrophils increased at day 21 post-tumour injection and decreased at the time that thrombosis occurred. Furthermore, the disappearance of hypercitrullinated neutrophils from the circulation coincided with the appearance of hypercitrullinated histone H3 (H3Cit) in the plasma of these mice. 101 Hypercitrullination of histones, which is believed to be mediated by neutrophil PADI4 enzyme, has been proposed to be a specific marker of NETosis. Hence, the observations in this model were thought to indicate a major role of tumour-induced NETs in cancer-associated thrombosis. In another study, orthotopic injection of the same cancer cell line into mice led to rapid development of metastases. Tumour-bearing mice exhibited a reduced time to jugular vein occlusion during venous thrombosis induced by Rose Bengal/laser photochemical injury compared with control mice, as well as reduction in time to arterial occlusion triggered in the carotid artery by ferric chloride injury. Pre-treatment of mice with DNAse 1 abolished the differences between tumour-bearing and control mice during both venous and arterial thrombosis challenges, further suggesting a role of NETs in these models of cancer-associated thrombosis. did not observe any thrombin generation in platelet-free plasma, or in a purified CS reconstituted in buffer.
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Activated Platelets
There is an extensive literature on the multiple roles of activated platelets in cancer-associated thrombosis. 108 Activation of the CS by activated platelets has been observed since the early 1980s. 109 Activated platelets can expose membrane-bound divalent ion-complexed polyphosphate nanoparticles, which resist circulating polyphosphatases and trigger FXII activation. 31 Released platelet polyphosphates have also been reported to activate the CS in vitro and in vivo. 
Glycosaminoglycans
At a molecular level, certain GAG species have been shown to activate FXII and the KAL-kinin pathway, with adverse clinical outcomes; the most notable example was when heparin batches contaminated by hypersulphated chondroitin sulphate moieties were inadvertently administered to patients. 25 Whether tumour cells can similarly produce atypical GAGs that activate the CS is unclear. Pan et al measured levels of glucosamine-and galactosamine-containing glycans as a putative mechanism for CS activation in cancer patients. 67 Galactosamine levels were increased in lung cancer but not in breast or pancreatic cancer patients compared with controls; on the other hand, glucosamine levels were increased in both lung and breast cancer patients compared with controls, although this was not observed in pancreatic cancer (►Table 2). Contact System Activation and Cancer Campello et al. 257
Catheter-Related Thrombosis
The use of venous catheters to facilitate chemotherapy, transfusions, parenteral nutrition and blood sampling is common in cancer patients. Up to 66 and 50% of patients with cancer and indwelling catheters develop insertion site thrombosis or pulmonary embolism, respectively.
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Reported risk factors for catheter-related thrombosis (CRT) in cancer patients include left-sided or superior vena cava insertion, chest radiotherapy, metastasis and elevated homocysteine levels. 115 The mechanisms by which catheters promote thrombosis are incompletely understood. Vessel injury and stasis caused by catheter insertion, cancer-induced 'hypercoagulability' and other comorbidities can all contribute to thrombosis. 115 Additionally, materials used to construct medical devices are inherently procoagulant to a greater or lesser extent. In contrast to the healthy endothelium, which actively resists thrombosis, artificial surfaces promote clotting through a complex series of interconnected processes that include protein adsorption and platelet and leukocyte adhesion and activation that ultimately leads to fibrin formation. 116 CS proteins including FXII, PK, HK and FXI adsorb to artificial surfaces, 117 and catheter segments shorten clotting times when introduced in re-calcified plasma ex vivo. This procoagulant effect is attenuated in the presence of CTI, and is abolished in FXII-or FXI-deficient plasma, indicating that clotting is mediated by CS activation. 118 Furthermore, contact of whole blood with some materials used to manufacture medical devices induces TF expression on monocytes and TF-dependent shortening of clotting time ex vivo. 117 Since monocytes adhere to catheter surfaces, it is therefore possible that activation of the extrinsic pathway also contributes to CRT. While the relative contribution of the intrinsic versus the extrinsic pathway is unknown, one can speculate that these two pathways act synergistically to promote CRT, especially in the context of cancer where circulating TF is likely to be present.
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Therapeutic Implications of Contact System Activation in Cancer
Current practice recommends the use of heparins for the treatment and prophylaxis of VTE, as well as the treatment of symptomatic CRT in patients with cancer. 121 These treatments are associated with bleeding side effects, which can be of major concern in patients with chemotherapyinduced thrombocytopenia, and in certain cancer types associated with a high risk of bleeding. The use of anticoagulation for routine prophylaxis of CRT is not recommended, as it largely fails to prevent CRT occurrence.
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Additionally, manufacturing catheters using biomaterials that are less thrombogenic would help to further reduce the incidence of CRT. Indeed, coating catheters with polyethylene glycol and CTI reduced protein adhesion, the ability to trigger FXII-dependent coagulation activation in plasma and a 2.5-fold prolongation of time to occlusion when inserted in the jugular vein of rabbits. Contact System Activation and Cancer Campello et al. 259 Although NETosis appears to play a role in cancerassociated thrombosis in animals, it remains unclear if this effect is due to direct CS activation. As TF is up-regulated in many cancers, it seems reasonable to propose that concomitant activation of both the intrinsic and extrinsic pathways acts synergistically to produce a highly prothrombotic state in cancer (►Fig. 3). It is tempting to speculate that while TF is the primary initiator, CS activation contributes to the amplification of thrombin generation. Future research should focus primarily on the standardization of methods to measure CS in clinical samples. This advance would further our understanding of the mechanisms by which CS activation contributes to non-CRT in humans. For CRT where CS activation is thought to play a major role, novel Fig. 3 Molecular activators of coagulation in cancer. Coagulation activation in cancer-associated thrombosis may be explained by contributions from both the tissue factor ('extrinsic') and FXII/FXI-dependent ('intrinsic') pathways. Tissue factor-bearing microvesicles may be released into the circulation by various tumour types and promote thrombin generation and ultimately thrombosis. FXII may be activated in vivo by a variety of negatively charged molecules. These could include phosphatidylserine (e.g. on microvesicles), glycosaminoglycans, polyphosphate, collagen, nucleic acids and misfolded proteins. Activation of the contact system in cancer would promote the generation of thrombin, thereby exacerbating thrombotic risk. Contact System Activation and Cancer Campello et al. 261
therapeutic options targeting contact pathways should be evaluated in well-designed clinical trials.
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